| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, N-Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine has no biological target. Its role is to provide phenylalanine residues in peptide chains with a protected phenolic side chain. The Fmoc protecting group enables standard Fmoc solid-phase peptide synthesis (SPPS) workflows. The tert-butoxycarbonylmethoxy group provides orthogonal protection for the phenolic oxygen.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of N-Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine is measured by coupling efficiency in solid-phase peptide synthesis. Typically, it is coupled to resin-bound amine using standard Fmoc-SPPS conditions. Purity is assessed by HPLC. No inherent biological activity is observed. |
| ln Vivo |
In vivo activity is not applicable.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow involves standard Fmoc solid-phase peptide synthesis procedures. Standard SPPS cycle: deprotect Fmoc with 20% piperidine in DMF, couple N-Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine (3 equiv.) with coupling reagents for 1-2 hours, wash, repeat. After synthesis, cleave with TFA/TIS/H₂O. Analyze by HPLC-MS.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on this compound.
|
| Animal Protocol |
In vivo animal experiments are not applicable.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties have not been characterized.
|
| Toxicity/Toxicokinetics |
The toxicological data are limited. Standard laboratory safety practices should be followed.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-993.
|
| Additional Infomation |
N-Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine is an advanced derivative of L-phenylalanine widely utilized in peptide synthesis. The tert-butoxycarbonylmethoxy group, coupled with the Fmoc protective moiety, ensures selective reactivity in solid-phase synthesis processes. The compound is for research use only. It is not a drug and has no clinical trials or approvals.
|
| Molecular Formula |
C30H31NO7
|
|---|---|
| Molecular Weight |
517.57
|
| Exact Mass |
517.21
|
| CAS # |
181951-92-8
|
| PubChem CID |
2756198
|
| Appearance |
White to off-white solid powder
|
| Density |
1.251 g/cm3
|
| Boiling Point |
699.6ºC at 760 mmHg
|
| Flash Point |
376.9ºC
|
| LogP |
5.332
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
38
|
| Complexity |
794
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)OC(=O)COC1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
HGZSQWKDOAHSLN-SANMLTNESA-N
|
| InChi Code |
InChI=1S/C30H31NO7/c1-30(2,3)38-27(32)18-36-20-14-12-19(13-15-20)16-26(28(33)34)31-29(35)37-17-25-23-10-6-4-8-21(23)22-9-5-7-11-24(22)25/h4-15,25-26H,16-18H2,1-3H3,(H,31,35)(H,33,34)/t26-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9321 mL | 9.6605 mL | 19.3211 mL | |
| 5 mM | 0.3864 mL | 1.9321 mL | 3.8642 mL | |
| 10 mM | 0.1932 mL | 0.9661 mL | 1.9321 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
